Selegiline can safely slow Parkinson’s disease

	Tweet

In patients with early Parkinson’s disease, selegiline and other drugs in a class called monoamine oxidase type B inhibitors are cheap and effective treatments that reduce disability and the need for levodopa, researcher report in this week’s British Medical Journal.

Their study findings also show that the drugs are not associated with increased mortality, as had been reported in an earlier study.

To further examine the risks and benefits of these drugs, University of Birmingham researcher Professor Keith Wheatley and colleagues conducted a review of 17 trials involving a total of 3525 patients with early Parkinson’s disease.

Their analysis showed no significant differences in mortality between patients on monoamine oxidase type B inhibitors and patients taking an inactive pill (placebo).

The researchers did find that patients given the drugs had better total scores, motor scores, and activities of daily living scores on a Parkinson’s disease rating scale at 3 months, compared with placebo subjects. Treated patients were also less likely to need extra levodopa or to develop motor fluctuations.

“Our review provides no evidence that mortality is increased by selegiline and suggests that this inexpensive drug could be one of the most clinically effective and cost-effective treatments available for early Parkinson’s disease,” the authors write. The evidence for other drugs in the class is more limited, they add.

The report of increased mortality, which came from a UK study in 1995, was probably a chance finding, the investigators suggest.

Further large-scale trials comparing monoamine oxidase type B inhibitors with other active agents are urgently needed, the UK investigators conclude.

British Medical Journal, August 14, 2004.

RELATED STORIES:
FDA Approves Relenza for Prevention of Seasonal Flu   Research opens door to vaccines that can circumvent maternal antibodies   Anti-parasite drugs effective in mothers, children   Novartis says leukemia drug helps when Gleevec fails   Roswell Park research aids development of myeloma drug   Statins do not prevent cancer, study says   Tamiflu best for bird flu, but avoid steroids   Dutch re-open some farms after dioxin scare   Pfizer stops ads for arthritis drug after study   Canada health panel says Vioxx pain drug safe enough   Hospital hygiene ‘improving’   Solution to Bacterial Mystery Promises New Drugs

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]